Skip to main content
    I

    IGC Pharma, Inc. (IGC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.19
    +0.01 (+7.43%)

    Market Cap: $20.42M

    Last updated: Nov 17, 2026 at 4:38 PM ET

    IGC Pharma, Inc. (IGC) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    IGC Pharma (IGC) has a market cap of $20.42M and an enterprise value of $21.17M. It kept -643.65% of revenue as net income over the last 12 months. Its share count is up 21.04% from a year earlier.

    Total Valuation

    Enterprise value is 3.68% above the market cap, as debt exceeds cash.

    Market Cap$20.42M
    Enterprise Value$21.17M
    Latest price (Nov 17, 2026)$0.19

    Key Dates

    Last Earnings DateNov 6, 2026
    Fiscal Year EndMarch

    Share Statistics

    The share count rose 9.13% in the quarter ended Sep 30, 2026 and grew 20.02% a year over 2 years.

    Shares Outstanding100.33M
    Shares Change (YoY)+21.04%
    Shares Change (QoQ)+9.13%
    Share Count Growth (2Y CAGR)+20.02%

    Valuation Ratios

    Forward P/S20.4x
    P/B Ratio3.0x
    P/TBV Ratio26.0x

    Price Statistics

    The stock is down 47.49% over 52 weeks and trades 24.00% below its 50-day average.

    Beta (1Y)1.16
    52-Week Change-47.49%
    1-Month Change-22.31%
    3-Month Change-34.10%
    6-Month Change-33.33%
    5-Year Change-86.79%
    10-Year Change-55.69%
    Total Return (1Y)-52.22%
    Total Return (5Y CAGR)-32.82%
    Max Drawdown (1Y)-52.56%
    Max Drawdown (3Y)-73.18%
    Sharpe Ratio (1Y)-1.28
    Correlation with SPY (1Y)0.30
    50-Day Average$0.25
    200-Day Average$0.27
    52-Week Range$0.17 to $0.36
    RSI (14 Days)37.1
    Average Volume (20 Days)460.65K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.39x current liabilities, and total debt is 0.18x shareholder equity.

    Current Ratio0.39x
    Quick Ratio0.19x
    Debt / Equity0.18x

    Returns and Efficiency

    Return on Capital Employed (ROCE)-122.34%
    ROA (5Y Average)-79.77%
    ROIC (5Y Average)-58.08%
    Asset Turnover0.13x

    Scores

    IGC has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $1.26M over the last 12 months is up 13.92% from the 12 months before.

    Revenue$1.26M
    Revenue Growth (YoY)+13.92%
    Gross Profit$208.00K
    Operating Income-$10.11M
    Pretax Income-$8.11M
    Net Income-$8.11M
    EBITDA-$7.87M
    EBIT-$8.11M
    Reported EPS (TTM)-$0.09

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 66.80% of the $9.73M in total assets.

    Cash and Equivalents$331.00K
    Total Debt$1.08M
    Net Debt$751.00K
    Net Debt Per Share$0.01
    Working Capital-$1.79M
    Shareholder Equity$6.50M
    Book Value Per Share$0.06
    Tangible Book Value$761.00K
    Tangible Book Per Share$0.01
    Total Assets$9.73M
    Total Liabilities$3.23M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$5.21M
    FCF Per Share-$0.05
    Depreciation and Amortization$236.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -802.70%.

    Gross Margin16.51%
    Operating Margin-802.70%
    Pretax Margin-643.65%
    Net Margin-643.65%
    EBITDA Margin-624.92%
    EBIT Margin-643.65%
    Gross Margin (5Y Average)46.05%

    Growth

    Revenue grew 9.19% a year over 3 years.

    Revenue Growth (3Y CAGR)+9.19%
    Revenue Growth (5Y CAGR)+311.92%
    Book Value Per Share Growth (2Y CAGR)-24.93%
    Tangible Book Per Share Growth (2Y CAGR)-68.25%

    Revenue and profit by year

    Stock Splits

    The last split was a 1-for-10 reverse split on Apr 19, 2013.

    Last Split DateApr 19, 2013
    Split TypeReverse split
    Split Ratio1:10

    Analyst Forecast

    Consensus estimates put revenue growth at -15.51% a year over the next fiscal year.

    Revenue Growth Forecast (1Y CAGR)-15.51%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About IGC

    What is IGC's market cap?

    IGC Pharma has a market cap of $20.42M. Its enterprise value, which adds debt and subtracts cash, is $21.17M.

    How many shares of IGC are outstanding?

    IGC Pharma has 100.33M shares outstanding. The count is up 21.04% from a year earlier.

    Does IGC pay a dividend?

    No. IGC Pharma does not pay a dividend.

    How much debt does IGC have?

    IGC Pharma has $1.08M of total debt and $331.00K of cash and equivalents, a net debt position of $751.00K.